On January 24, the US Food and Drug Administration (FDA) released new information to increase awareness of recent updates to capecitabine and fluorouracil product labeling related to risks associated with dihydropyrimidine dehydrogenase deficiency.
For more information, read the FDA announcement.
Posted on 1/28/2025
Understanding both the benefits to be had from offering BsAb therapy to its community and the scope of this undertaking, Vanderbilt-Ingram Cancer Center took a novel approach with its APP-led BsAb step-up dosing clinic, which won the program a 2026 ACCC Innovator Award.
